

PROGRAM ANNOUNCEMENT



The Mesothelioma Applied Research Foundation

First International Symposium on Malignant Mesothelioma

Chairmen:

Nicholas J. Vogelzang, MD

Director, Nevada Cancer Institute
Las Vegas, Nevada

Harvey I. Pass, MD

Chief, Thoracic Oncology
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

October 14-16, 2004



MGM Grand Hotel

Las Vegas,
Nevada



Postgraduate Institute
for Medicine



MEDIDIGMS™
Developing Medical Paradigms Through Education



First International Symposium

Program Overview

The First International Symposium on Malignant Mesothelioma is uniquely designed to bring together the entire mesothelioma-concerned community. The symposium combines a high-level scientific/medical conference with material directly relevant to patients, family members and others interested in the disease. The two-day Scientific Meeting, organized and chaired by Dr. Nicholas Vogelzang and Dr. Harvey Pass, will provide the world's mesothelioma experts the opportunity to share, and sharpen, their understandings of the disease, and so collectively advance the science and our progress toward effective treatments. Front-line physicians will learn of the recent advances, the treatments available now, and the promising emerging treatments.

Patients, family members, volunteers and other patient advocates will gain knowledge, encouragement and hope as they observe first-hand the dedication and brilliance of those who are working so passionately to unlock the secrets of this disease. "Ask the Professors" and "One-on-One Questions with the Panelists" sessions are specifically designed within the Scientific Meeting to help these non-experts digest the scientific material presented and allow them to follow up with their own questions, one-on-one with the experts. Additionally, the separate Patient Advocacy Workshops day is geared directly toward patients, family members, volunteers and advocates, with highly practical content aimed to help them as they deal with the disease and its effects and/or as they seek to help others.

This convergence of the entire mesothelioma community promises profound opportunities for networking, sharing, and increasing not just scientific, but also personal understanding of the disease. Patients, family members, survivors, advocates, and scientific and medical experts will all have the opportunity to meet with, share with and encourage each other. Specially designed events, including the Tribute to Our Heroes Remembrance Ceremony, will facilitate this community-building. Also, a delightful evening is in store for all attendees at Friday's Gala Reception and Dinner, featuring a talk by Jordan Zevon, presentation of the Congressman Bruce Vento Hope Builder Award to Senator Patty Murray, individual acknowledgement and recognition of each patient in attendance, and the Keynote Speech by the Honorable Harry Reid, Nevada Senator, Democratic Whip, and a wonderful speaker.

All of this occurs at the unsurpassed MGM Grand in Las Vegas. Las Vegas is famous for its casinos, but was chosen as the ideal location for the Symposium because of its excellent convention and hotel facilities, ease and inexpensiveness of air travel, and beautiful mid-October weather.

I look forward to seeing you!



Chairmen's Welcome

page 2

Patient Advocacy Workshops, October 14

pages 3-4

Scientific Meeting, October 15-16

pages 5-8

Symposium Registration

page 9

Hotel Registration

page 10

Christopher E. Hahn

Executive Director

The Mesothelioma Applied Research Foundation

Chairmen's Welcome

Mesothelioma was long regarded pessimistically as an “orphan” disease. However, interest in the disease in the U.S. and worldwide is growing as, on the one hand, its incidence continues to increase, but on the other hand, new optimism takes hold regarding the potential for successful therapy. New technologies employing genomics and proteomics, along with standardization of clinical and pathological staging, are improving diagnosis and pathologic characterization. Improved chemotherapy regimens, and innovations in multi-modal approaches using surgery and radiation, have resulted in significant therapeutic advances. Novel emerging treatments hold promise for further improving outcomes.

The First International Symposium on Malignant Mesothelioma is thus a timely opportunity for expert review of the current state of knowledge and the developing advances. We look forward to your participation.



Nicholas J. Vogelzang, M.D.
Director, Nevada Cancer Institute



Harvey I. Pass, M.D.
Chief, Thoracic Oncology, Karmanos Cancer Institute
Professor of Surgery and Oncology, Wayne State University



First International Symposium

PATIENT ADVOCACY WORKSHOPS

THURSDAY, OCTOBER 14, 2004

- 8:00 - 8:05 am** Welcome and Opening Remarks
Christopher E. Hahn, MARF Executive Director
- 8:05 - 8:25 am** Curing Mesothelioma: Where are the Resources?
Roger G. Worthington, MARF Founding Director
- 8:25 - 8:45 am** The Role U.S. Corporations Can Play
Philip McWeeny, Vice President, General Corporate Counsel, Owens Illinois
- 8:45 - 9:15 am** Federal Efforts to Identify Mesothelioma and Asbestos Related Disease
Vikas Kapil, DO, MPH, FACOEM, Senior Medical Officer, U.S. Agency For Toxic Substances and Disease Registry, Centers for Disease Control
- 9:15 - 9:45 am** Working to Eradicate Mesothelioma
Christopher E. Hahn, MARF Executive Director
- 9:45 - 9:55 am** BREAK
- 9:55 - 2:10 pm** Mesothelioma Medical Treatment – Practical Aspects
Mary Hesdorffer, RN, Clinical Research Nurse, NY Presbyterian Hosp/ Columbia University
Laura Roy, RN, Clinical Coordinator, Multidisciplinary Thoracic Program, Karmanos Cancer Institute
- * Understanding Malignant Mesothelioma
 - * The ABC's of Clinical Trials
 - * Current and Future Treatment Options
 - * Symptom and Side Effect Management
 - * Working with Your Medical Team for Maximum Effectiveness
 - * Educational Resources
 - * Questions and Answers/Discussion
- 11:50 - 1:05 pm** LUNCH
Special Lunch Session (for all MARF volunteers and those interested in joining as volunteers)





PATIENT ADVOCACY WORKSHOPS

- 2:10 - 6:15 pm** Cancer and the Whole Person: Strategies for Emotional Recovery through Diagnosis, Treatment, Caregiving and Loss
Presented in collaboration with the Association of Oncology Social Workers
Linda Diaz, MSW, ACSW, AOSW Education Chair
Les Gallo-Silver, MSW
Roelina VanZanten, MSW, OSWC
Judy Buckles, ASW, and Kim Buckles-Tucker, BSW (Judy Buckles and Kim Buckles-Tucker lost their husband / father, Lewis Buckles, to mesothelioma in 1997)
- 2:10 - 2:25 pm** Practical Strategies for Managing Anger, Regret, Fear and Social Injustice
- 2:25 - 2:40 pm** Self Care for the Caregiver
- 2:40 - 2:55 pm** Managing your Role as an Advocate: Navigating the Emotional Waters
- 2:55 - 3:05 pm** BREAK
- 3:05 - 3:30 pm** Surviving After the Loss of a Loved One
- 3:30 - 4:45 pm** Networking (Each group will be professionally facilitated and designed to promote sharing of concerns as well as problem solving):
Group A: Recommended for patients in treatment (families may attend if desired)
Group B: Recommended for Caregivers (patients may attend if desired)
Group C: Recommended for those coping with loss of a loved one
- 4:45 - 4:55 pm** BREAK
- 4:55 - 5:10 pm** Summary: The Definition of Healing
- 5:10 - 6:10 pm** Pain Management
Matt Loscalzo, MSW
- 6:10 - 7:20 pm** A Tribute to Our Heroes - Ceremony of Remembrance for Loved Ones Lost to Mesothelioma with special music and memorial display area
- 7:00-9:00 pm** Group Reception





PROGRAM DESCRIPTION

Although the incidence of malignant mesothelioma in the United States is low (approximately 2500 cases per year), median survival is only 6 to 15 months and the 5-year survival rate is <5%. Malignant mesothelioma is often misdiagnosed, due in part to a lack of definitive immunohistochemical staining and a consistent staging system. However, new technologies employing genomics and proteomics, coupled with standardization of clinical and pathological staging, are improving diagnosis and pathologic characterization. Recent advances in first- and second-line chemotherapy regimens as well as innovations in combined-modality approaches using surgery and radiation therapy have resulted in significant therapeutic advances. Novel emerging treatments such as gene therapy and immunotherapy hold promise for further improving outcomes. In this meeting, experts in the field will review (1) the pathogenesis of malignant mesothelioma, (2) detection, staging, and classification, (3) use of genomics and proteomics to assess risk, (4) current use of surgery and post-operative radiation therapy, and (5) novel approaches for the treatment of malignant mesothelioma.

EDUCATIONAL OBJECTIVES:

After participating in this activity, physicians should be able to:

1. Define the pathogenesis of malignant mesothelioma, and the contribution of exposure to asbestos and erionite to the development of disease.
2. Evaluate the use of genomics and proteomics in assessing risk for development of this disease, and identify significant prognostic factors related to therapeutic outcome.
3. State methods used for staging, diagnosis, and pathologic classification of disease.
4. Summarize the optimal use of surgery and radiation therapy in the treatment of malignant mesothelioma.
5. Identify commonly used and emerging chemotherapy regimens, including first- and second-line chemotherapy as well as neoadjuvant/adjuvant therapy, and apply these to improve patient outcomes.

6. Comprehend new therapeutic approaches under investigation such as immunotherapy and gene therapy, and consider enrolling suitable patients in clinical trials.

TARGET AUDIENCE

This meeting is targeted to medical, surgical, and radiation oncologists, pathologists, and other physicians involved in the care and treatment of patients with malignant mesothelioma. Patients, family members and others interested in mesothelioma are invited to attend, and will have the opportunity for questions at the Ask the Professors and One-on-One Questions with the Panelists sessions.

ACCREDITATION STATEMENT:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine and MediDigs, L.P. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT:

The Postgraduate Institute for Medicine designates this educational activity for a maximum of 14 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

FACULTY DISCLOSURE STATEMENT:

All faculty participating in continuing education activities sponsored by the Postgraduate Institute for Medicine are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.

The chairmen and presenters would like to inform you that the meeting presentations may contain off-labeled prescribing information.

 FACULTY 

Steven M. Albelda, MD

University of Pennsylvania

Hedy Lee Kindler, MD

University of Chicago

Richard Alexander, MD

National Cancer Institute

Brooke T. Mossman, PhD

University of Vermont College of Medicine

Raphael Bueno, MD

*Harvard Medical School
Brigham & Women's Hospital*

Jill Ohar, MD

Wake Forest University Medical Center

Robert B. Cameron, MD

David Geffen School of Medicine at UCLA

Edward Patz, Jr, MD

Duke University Medical Center

Michele Carbone, MD

Loyola University Medical Center

Nick Pavlakis, Bsc, MBBS, MMED

Royal North Shore Hospital-Australia

Raja M. Flores, MD

Memorial Sloan-Kettering Cancer Center

W. Roy Smythe, MD

*Texas A&M University
Scott and White Hospital*

Raffit Hassan, MD

National Cancer Institute

David Sugarbaker, MD

*Harvard Medical School
Brigham & Women's Hospital*

Elliott Kagan, MD

*Uniformed Services
University of the Health Sciences*

Robert N. Taub, MD

Columbia University Medical Center

W. Martin Kast, PhD

*University of Southern California
Norris Comprehensive Cancer Center*

Joseph R. Testa, PhD

Fox Chase Cancer Center



First International Symposium

Friday, October 15, 2004

Co-Moderators: Harvey Pass and Nicholas Vogelzang

8:00 – 8:05 am	Introduction	
8:05 – 8:25 am	History of Mesothelioma	<i>TBD</i>
8:25 – 8:30 am	Q&A	
8:30 – 8:50 am	Pathogenesis of Mesothelioma	<i>Brooke Mossman</i>
8:50 – 8:55 am	Q&A	
8:55 – 9:15 am	Determination of Asbestos Exposure by Pathology and Clinical History	<i>Elliott Kagan</i>
9:15 – 9:20 am	Q&A	
9:20 – 9:40 am	Prediction of Mesothelioma Risk	<i>Jill Ohar</i>
9:40 – 9:45 am	Q&A	
9:45 – 10:00 am	BREAK	
10:00 – 10:20 am	Inherited Mesothelioma	<i>Michele Carbone</i>
10:20 – 10:25 am	Q&A	
10:25 – 10:45 am	Malignant Mesothelioma in Turkey, and Erionite	<i>TBD</i>
10:45 – 10:50 am	Q&A	
10:50 – 11:10 am	Molecular Biology of Mesothelioma	<i>Joseph Testa</i>
11:10 – 11:15 am	Q&A	
11:15 – 11:35 am	Proteomics in Mesothelioma	<i>Harvey Pass</i>
11:35 – 11:40 am	Q&A	
11:40 – 12:00 noon	Genomics in Mesothelioma	<i>Raphael Bueno</i>
12:00 – 12:05 pm	Q&A	
12:05 – 1:00 pm	LUNCH	
1:00 – 1:20 pm	Staging of Mesothelioma	<i>Raja Flores</i>
1:20 – 1:25 pm	Q&A	
1:25 – 1:45 pm	Radiographic Imaging	<i>Edward Patz</i>
1:45 – 1:50 pm	Q&A	
1:50 – 2:10 pm	Standard Morphology and Cytology of Malignant Mesothelioma	<i>TBD</i>
2:10 – 2:15 pm	Q&A	
2:15 – 2:35 pm	Prognostic Factors in Mesothelioma	<i>Nicholas Vogelzang</i>
2:35 – 2:40 pm	Q&A	
2:40 – 3:40 pm	Ask the Professors Panel	<i>Faculty</i>
3:40 – 4:40 pm	One-on-One Questions with the Panelists	
6:30 – 9:00 pm	Reception and Gala Dinner	
	<i>In Memory of Warren Zevon — Jordan Zevon</i>	
	<i>Congressman Bruce Vento Hope Builder Award — Presented to Patty Murray,</i>	
	<i>United States Senator from Washington</i>	
	<i>Honoring Our Heroes — Patients in attendance will be individually acknowledged</i>	
	<i>Keynote Speaker — Harry Reid, United States Senator from Nevada, Democratic Minority Whip</i>	
	<i>(subject to legislative session)</i>	



Saturday, October 16, 2004

Co-Moderators: Harvey Pass and Nicholas Vogelzang

8:00 – 8:05 am	Introduction	
8:05 – 8:25 am	Management of Pleural Effusions	<i>Robert Cameron</i>
8:25 – 8:30 am	Q&A	
8:30 – 8:50 am	Surgery, Pre/Post-operative Chemotherapy, and Radiation Therapy	<i>David Sugarbaker</i>
8:50 – 8:55 am	Q&A	
8:55 – 9:15 am	Surgery and Post-operative Radiotherapy	<i>Roy Smythe</i>
9:15 – 9:20 am	Q&A	
9:20 – 9:40 am	Novel Therapies Combined with Surgery	<i>Harvey Pass</i>
9:40 – 9:55 am	BREAK	
9:55 – 10:00 am	Q&A	
10:00 – 10:20 am	Chemotherapy for Pleural Mesothelioma	<i>Nick Pavlakis</i>
10:20 – 10:25 am	Q&A	
10:25 – 10:45 am	Novel Agents for Mesothelioma	<i>Hedy Kindler</i>
10:45 – 10:50 am	Q&A	
10:50 – 11:10 am	Immunotherapeutic Approaches and Vaccination Strategies	<i>W. Martin Kast</i>
11:10 – 11:15 am	Q&A	
11:15 – 11:35 am	Gene Therapy	<i>Steven Albelda</i>
11:35 – 11:40 am	Q&A	
11:40 – 1:00 pm	LUNCH, Poster Session	
1:30 – 1:50 pm	Peritoneal Mesothelioma	<i>Raffit Hassan</i>
1:50 – 1:55 pm	Q&A	
1:55 – 2:15 pm	The Columbia University Experience with Peritoneal Mesothelioma	<i>TBD</i>
2:15 – 2:20 pm	Q&A	
2:20 – 2:40 pm	Treatment of Peritoneal Mesothelioma	<i>Richard Alexander</i>
2:40 – 2:45 pm	Q&A	
2:45 – 3:15 pm	Practical Aspects and Future Directions: Chemotherapy and Surgical Panel Discussion	
3:15 – 4:15 pm	Ask the Professors Panel	<i>Faculty</i>
4:15 – 5:15 pm	One-on-One Questions with the Panelists	





First International Symposium

Symposium Registration

To register for either the Patient Advocacy Workshop or the Scientific Meeting, or both, please complete the attached registration form and forward with your payment to the address below. Registrants for either the Patient Advocacy Workshop or the Scientific Meeting are entitled to admittance into the other at no additional fee. To register by fax, please fax to (928) 962-4417 (credit cards only).

Mail to:

MediDigs, L.P.
100 W. Southlake Blvd., Suite 142
Southlake, Texas 76092

For additional Symposium Information:

Medical Education Department
Phone: (866) 748-5140
Fax: (928) 962-4417
E-mail: cme@medidigs.com

* A cancellation fee of 75% will be assessed on registration refunds requested after October 2, 2004. No refunds will be made after October 12, 2004.

NAME _____ CREDENTIALS _____

PROFESSIONAL TITLE: _____

AFFILIATION _____

MAILING ADDRESS _____

CITY _____ PROV/STATE _____ COUNTRY _____ ZIP/POSTAL CODE _____

PHONE _____ FAX _____

E-MAIL _____

SPECIALTY: MEDICAL ONCOLOGY SURGICAL ONCOLOGY RADIATION ONCOLOGY PULMONOLOGIST THORACIC SURGEON
 OCCUPATIONAL HEALTH OTHER

PLEASE CHECK THE APPROPRIATE CATEGORY

BEFORE SEPTEMBER 15 / AFTER SEPTEMBER 15

GROUP I	Patient* • Family Member*	<input type="checkbox"/> \$150.00	<input type="checkbox"/> \$175.00
GROUP II	Allied Health Care Practitioner • Fellows in Training	<input type="checkbox"/> \$150.00	<input type="checkbox"/> \$175.00
GROUP III	Medical/Academic/Scientific • Government • Nonprofit Advocacy	<input type="checkbox"/> \$325.00	<input type="checkbox"/> \$375.00
GROUP IV	Other Professionals	<input type="checkbox"/> \$750.00	<input type="checkbox"/> \$1000.00

*For patients and family members, financial aid scholarships, and 100% refunds for cancellations due to medical needs are available. Contact Ray Rengo at r-rengo@marf.org.

Americans with Disabilities Act (if applicable)

Event staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.).

PLEASE SPECIFY _____

PAYMENT MAY BE MADE BY: CHECK VISA MASTERCARD AMERICAN EXPRESS

Please make checks payable to **MediDigs**

CARD NUMBER _____ EXPIRATION DATE _____

NAME ON CHARGE CARD _____ SIGNATURE _____



CREDIT CARD SECURITY ID # _____



United Airlines is the official airline of the First International Symposium on Malignant Mesothelioma Applied Research Foundation. Reservations booked by you or your travel agent on United, Shuttle by United or United Express 30 days prior to travel will receive a 10% discount on the lowest published fare, or a 5% discount if booked less than 30 days prior. **Call United's Specialized Meeting Reservation Center at 1-800-521-4041** and reserve using Meeting ID Number 522AG

HOTEL RESERVATION FORM

October 14-16, 2004

The MGM Grand policy requires that all rooms blocked for this event that are not reserved will be released on **September 22, 2004**. Reservations received after this date will be processed on a "space-available basis". [The MGM Grand Hotel requires you to register directly with the hotel to secure a hotel room for this symposium.](#) Please use the code "Mesothelioma Symposium" or "MRF 001" for your reservation.

THE HOTEL WILL MAKE EVERY EFFORT TO HONOR SPECIFIC ROOM REQUESTS. If not possible, the best substitution will be made.

Please Check Desired Occupancy: SINGLE \$159.00 DOUBLE \$159.00

Arrival Date _____ Departure Date _____ Check-In Time: 3:00 PM – Check-Out Time: 11:00 AM

Please complete and fax to: MGM Grand Hotel
3799 Las Vegas Boulevard South
Las Vegas, Nevada 89109
(FAX) 702-891-3136

For Phone Reservations: 1-800-929-1111

ROOMS TO BE OCCUPIED BY: (Type or print)

NAME _____

MAILING ADDRESS _____

CITY _____ STATE _____ ZIP CODE _____

NAME _____

MAILING ADDRESS _____

CITY _____ STATE _____ ZIP CODE _____

CREDIT CARD INFORMATION FOR ROOM DEPOSIT(S):

Credit Card Name & Number _____ EXP ____ / ____

Card Holder Name _____

Credit Card Holder Authorized Signature _____

Home Phone (_____) _____ Business Phone (_____) _____

E-Mail _____

RATES ARE SUBJECT TO A 9% STATE SALES TAX.

DEPOSIT AND CANCELLATION POLICY: A deposit representing one night's room rate, service charge and tax will be charged at the time the reservation is made. Your advanced deposit will be applied as an early departure fee for departures prior to the reserved departure date. Deposits to be made by credit card. The MGM Grand must receive notice of any cancellation at least 24 hours prior to date of arrival in order to refund a deposit. The reservation deadline is **September 22, 2004**. Confirmation will be received by mail.



**100 West Southlake Blvd., Suite 142
Southlake, Texas 76092**